BioMarin's Morquio A drug confers 'modest' benefit: FDA review

BioMarin's Morquio A drug confers 'modest' benefit: FDA review

(Reuters) – An experimental drug to treat a rare genetic disorder that causes skeletal malformation and a host of related lung, eye, ear and heart problems confers "modest" benefit, according to an initial review by the U.S. Food and Drug Administration.

10
Like
Save

Comments

Write a comment

*